<html><body><pre>
[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1473 Introduced in House (IH)]

&lt;DOC&gt;






117th CONGRESS
  1st Session
                                H. R. 1473

 To require the Commissioner of Food and Drugs and the Director of the 
 Centers for Disease Control and Prevention to report to Congress all 
serious adverse events that are reported to such agencies in connection 
   with administration of a COVID-19 vaccine, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 1, 2021

  Mr. Steube introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To require the Commissioner of Food and Drugs and the Director of the 
 Centers for Disease Control and Prevention to report to Congress all 
serious adverse events that are reported to such agencies in connection 
   with administration of a COVID-19 vaccine, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Vaccine Transparency Act of 2021''.

SEC. 2. REPORTS TO CONGRESS ON SERIOUS ADVERSE EVENTS IN CONNECTION 
              WITH COVID-19 VACCINES.

    (a) In General.--Not later than 60 days after the date of enactment 
of this Act, and every 60 days thereafter, the Commissioner of Food and 
Drugs and the Director of the Centers for Disease Control and 
Prevention, acting jointly, shall submit a report to the Congress on 
all serious adverse events that are reported--
            (1) to either agency pursuant to the Vaccine Adverse Event 
        Reporting System or otherwise during the period covered by the 
        report; and
            (2) in connection with a COVID-19 vaccine.
    (b) Initial Report.--The reporting period of the initial report 
under subsection (a) shall begin on the date when the Commissioner of 
Food and Drugs first authorized emergency use of a COVID-19 vaccine 
under section 564 of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360bbb-3).
                                 &lt;all&gt;
</pre></body></html>
